Major Depressive Disorder Clinical Trial
Official title:
Dopamine Neurotransmission in Major Depression
The overall aim of this study is to utilize an integrative research model in order to
dynamically assess reward-related dopamine (DA) transmission in major depressive disorder
(MDD) and test the role of dysfunctional DA release in depression and anhedonia.
The first arm of this line of research (PET scan) aims to investigate phasic DA release in
MDD during incentive motivation. The investigators will utilize an established molecular
imaging technique to measure striatal DA release dynamically during performance of testing
and control versions of a monetary incentive delay task, which involves anticipation and
receipt of monetary rewards. In doing so, this experiment will link together independent
lines of research that have associated depression with decreased hedonic responsiveness,
impaired reinforcement learning and dysfunctional DA transmission. We hypothesize that,
relative to matched controls, unmedicated MDD subjects will show reduced reward-related
ligand (11C-raclopride) displacement. Reduced ligand displacement will be interpreted as
indicating reduced task-induced release of endogenous striatal DA in response to
reward-predicting cues and unpredictable reward in MDD subjects.
In the second arm of this research (EEG recording), the investigators aim to probe the
spatio-temporal dynamics of brain mechanisms underlying positive and negative reinforcement
learning in MDD and their relations to phasic DA. Participants will perform the
probabilistic stimulus selection task (PSST) while event-related potentials (ERPs) are
collected. The investigators expect that, relative to matched controls, unmedicated MDD
subjects will show reduced positive reinforcement learning, potentiated negative
reinforcement learning, and larger (i.e., more negative) feedback-related negativity (FRN)
in response to positive reinforcement (indicative of reduced DA transmission). Moreover, the
investigators hypothesize that a more negative FRN in response to positive reinforcement
will be associated with decreased striatal raclopride displacement (i.e., lower release of
endogenous DA) as measured by PET in the first part of the study. This experiment will
investigate the effects of blunted DA transmission on behavioral and ERP markers of both
positive and negative reinforcement learning.
n/a
Observational Model: Case Control
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05537558 -
Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
|
||
Terminated |
NCT02192099 -
Open Label Extension for GLYX13-C-202, NCT01684163
|
Phase 2 | |
Completed |
NCT03142919 -
Lipopolysaccharide (LPS) Challenge in Depression
|
Phase 2 | |
Recruiting |
NCT05547035 -
Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders
|
N/A | |
Terminated |
NCT02940769 -
Neurobiological Effects of Light on MDD
|
N/A | |
Recruiting |
NCT05892744 -
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
|
Phase 4 | |
Recruiting |
NCT05537584 -
SMART Trial to Predict Anhedonia Response to Antidepressant Treatment
|
Phase 4 | |
Active, not recruiting |
NCT05061706 -
Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
|
Phase 3 | |
Completed |
NCT04479852 -
A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder
|
Phase 2 | |
Recruiting |
NCT04032301 -
Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans
|
Phase 1 | |
Recruiting |
NCT05527951 -
Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study
|
N/A | |
Completed |
NCT03511599 -
Cycloserine rTMS Plasticity Augmentation in Depression
|
Phase 1 | |
Recruiting |
NCT04392947 -
Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation
|
N/A | |
Recruiting |
NCT05895747 -
5-HTP and Creatine for Depression R33 Phase
|
Phase 2 | |
Recruiting |
NCT05273996 -
Predictors of Cognitive Outcomes in Geriatric Depression
|
Phase 4 | |
Recruiting |
NCT05813093 -
Interleaved TMS-fMRI in Ultra-treatment Resistant Depression
|
N/A | |
Recruiting |
NCT05135897 -
The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
|
||
Enrolling by invitation |
NCT04509102 -
Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder
|
Early Phase 1 | |
Recruiting |
NCT06026917 -
Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET)
|
Phase 4 | |
Recruiting |
NCT06145594 -
EMA-Guided Maintenance TMS for Depression
|
N/A |